July 27 (Reuters) - Antisense Therapeutics Ltd ANP.AX
* FDA has told ANP that modifications to proposed clinical trial are needed in order for FDA to clear the IND to proceed
* Company has been in recent communications with FDA in regard to ATL1102 for Multiple Sclerosis Phase IIb IND application